Good
Mostly Aligned
Patient Risk:
Low
Summary
Some claims align with the label excerpt (Ontralfy indicated for spasticity in adults; tizanidine is a central alpha-2-adrenergic agonist consistent with a muscle-relaxant description). However, several claims are not supported by the provided label excerpts (brand name, frequency phrasing like “often,” country/formulation variability).
Category Scores
Accurate Statements
Tizanidine is used to treat muscle spasticity.
Supported by Ontralfy (tizanidine) indication: “Ontralfy is indicated for the treatment of spasticity in adults.” (Section 1)
Unsupported Statements
Tizanidine is sold under the brand name Zanaflex.
No brand-name equivalence is provided in the supplied label excerpts.
Tizanidine is a muscle relaxant.
The excerpt provided describes the mechanism as “a central alpha-2-adrenergic receptor agonist” and indication for spasticity, but does not explicitly label tizanidine as a “muscle relaxant.”
Muscle spasticity treated with tizanidine is often from multiple sclerosis.
No information in the supplied excerpts about etiologies of spasticity or frequency (e.g., multiple sclerosis) is provided.
Muscle spasticity treated with tizanidine is often from spinal cord injury.
No information in the supplied excerpts about etiologies of spasticity or frequency (e.g., spinal cord injury) is provided.
The available product of tizanidine can vary by country and formulation.
The supplied excerpts do not address cross-country availability or formulation variability.
Contradictions
Important Omissions
None identified as material omissions relative to the specific claims provided, because the label excerpts supplied do not include the missing safety/population details for these particular claims (e.g., boxed warnings, pregnancy/lactation, pediatric dosing).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Unsupported statements are mainly about brand naming, etiologies (“often”), and product availability rather than dosing/contraindications; therefore no direct dosing/safety misapplication is evidenced from the provided excerpt comparisons.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the provided Ontralfy label excerpts, particularly brand name, “muscle relaxant” wording, etiologies with frequency (“often”), and country/formulation variability.
Suggested Improvement
Limit statements to label-supported content from the provided excerpts (e.g., indication for spasticity in adults). Remove or qualify unsupported claims unless the exact FDA label text supporting them is provided.